These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5985 related articles for article (PubMed ID: 23684677)

  • 1. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction.
    van Heerebeek L; Hamdani N; Falcão-Pires I; Leite-Moreira AF; Begieneman MP; Bronzwaer JG; van der Velden J; Stienen GJ; Laarman GJ; Somsen A; Verheugt FW; Niessen HW; Paulus WJ
    Circulation; 2012 Aug; 126(7):830-9. PubMed ID: 22806632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction.
    Franssen C; Chen S; Unger A; Korkmaz HI; De Keulenaer GW; Tschöpe C; Leite-Moreira AF; Musters R; Niessen HW; Linke WA; Paulus WJ; Hamdani N
    JACC Heart Fail; 2016 Apr; 4(4):312-24. PubMed ID: 26682792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction.
    Hamdani N; Bishu KG; von Frieling-Salewsky M; Redfield MM; Linke WA
    Cardiovasc Res; 2013 Mar; 97(3):464-71. PubMed ID: 23213108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
    Shah SJ; Kitzman DW; Borlaug BA; van Heerebeek L; Zile MR; Kass DA; Paulus WJ
    Circulation; 2016 Jul; 134(1):73-90. PubMed ID: 27358439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction.
    Konstantinou DM; Chatzizisis YS; Giannoglou GD
    Pharmacol Ther; 2013 Nov; 140(2):156-66. PubMed ID: 23792088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction.
    Paulus WJ; Dal Canto E
    JACC Heart Fail; 2018 Jan; 6(1):1-7. PubMed ID: 29284577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.
    Mohammed SF; Hussain S; Mirzoyev SA; Edwards WD; Maleszewski JJ; Redfield MM
    Circulation; 2015 Feb; 131(6):550-9. PubMed ID: 25552356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
    Mátyás C; Németh BT; Oláh A; Török M; Ruppert M; Kellermayer D; Barta BA; Szabó G; Kökény G; Horváth EM; Bódi B; Papp Z; Merkely B; Radovits T
    Eur J Heart Fail; 2017 Mar; 19(3):326-336. PubMed ID: 27995696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.
    Ter Maaten JM; Damman K; Verhaar MC; Paulus WJ; Duncker DJ; Cheng C; van Heerebeek L; Hillege HL; Lam CS; Navis G; Voors AA
    Eur J Heart Fail; 2016 Jun; 18(6):588-98. PubMed ID: 26861140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.
    Hamdani N; Franssen C; Lourenço A; Falcão-Pires I; Fontoura D; Leite S; Plettig L; López B; Ottenheijm CA; Becher PM; González A; Tschöpe C; Díez J; Linke WA; Leite-Moreira AF; Paulus WJ
    Circ Heart Fail; 2013 Nov; 6(6):1239-49. PubMed ID: 24014826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited.
    Paulus WJ; Zile MR
    Circ Res; 2021 May; 128(10):1451-1467. PubMed ID: 33983831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel paradigms for heart failure with preserved ejection fraction.
    Jaroch J; Łoboz-Grudzień K
    Przegl Lek; 2016; 73(6):413-8. PubMed ID: 29671304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial reverse remodeling: how far can we rewind?
    Rodrigues PG; Leite-Moreira AF; Falcão-Pires I
    Am J Physiol Heart Circ Physiol; 2016 Jun; 310(11):H1402-22. PubMed ID: 26993225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation in HFpEF: Key or circumstantial?
    van Empel V; Brunner-La Rocca HP
    Int J Cardiol; 2015; 189():259-63. PubMed ID: 25897922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart failure with preserved ejection fraction in hypertension.
    Teo LY; Chan LL; Lam CS
    Curr Opin Cardiol; 2016 Jul; 31(4):410-6. PubMed ID: 27070649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction.
    Saiki H; Moulay G; Guenzel AJ; Liu W; Decklever TD; Classic KL; Pham L; Chen HH; Burnett JC; Russell SJ; Redfield MM
    Am J Physiol Heart Circ Physiol; 2017 Aug; 313(2):H392-H407. PubMed ID: 28550173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
    Alex L; Russo I; Holoborodko V; Frangogiannis NG
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of Coronary Microvascular Dysfunction and Diffuse Myocardial Fibrosis (Measured by Cardiovascular Magnetic Resonance) in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Löffler AI; Pan JA; Balfour PC; Shaw PW; Yang Y; Nasir M; Auger DA; Epstein FH; Kramer CM; Gan LM; Salerno M
    Am J Cardiol; 2019 Nov; 124(10):1584-1589. PubMed ID: 31575425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin.
    Zile MR; Baicu CF; Ikonomidis JS; Stroud RE; Nietert PJ; Bradshaw AD; Slater R; Palmer BM; Van Buren P; Meyer M; Redfield MM; Bull DA; Granzier HL; LeWinter MM
    Circulation; 2015 Apr; 131(14):1247-59. PubMed ID: 25637629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 300.